Who We Are
A pioneer and leading voice in the advancement of medicinal cannabis therapeutics
Reno J. Calabrigo, Director of Constance LifeSciences Corp., is a Canadian industry veteran and held previous positions as President, Chief Executive Officer, Chief Financial Officer, Secretary & Treasurer at Resgreen Group International, Inc.
Mr. Calabrigo obtained a Bachelor of Arts from the Simon Fraser University in 1981 and obtained his Master’s Degree in Business Administration from the University of Idaho in 1983.
Constance Finley, founder and CEO of Constance Therapeutics Inc., was inspired by her own personal experience with a chronic illness.
After nearly dying from the pharmaceuticals prescribed to help alleviate pain and inflammation caused by a rare autoimmune disease, Finley turned to medicinal cannabis for relief.
She quickly became fascinated with the science behind the medicinal benefits of cannabis and has rapidly earned an international reputation as perhaps the world’s premiere expert in using THC – and CBD-laden cannabis oils. Based on her research, Finley became determined to make standardized, whole plant cannabis extracts that incorporate all the naturally occurring cannabinoids, terpenes and flavonoids in cannabis, and are safe for those with compromised immune systems.
Today, her mission is to create awareness and advocate for the enormous potential that whole-plant cannabis offers the seriously ill among us. In so many ways her quest and leadership has launched an industry that is redefining the kinds of options available to the sick as they fight to regain their quality of life.
Prior to Constance Therapeutics, Finley was founder and CEO of Housing Allies, Inc., where she pioneered the use of tax credits to create low-income housing for the working poor and ill. Finley holds a Master of Arts in Clinical Psychology from the University of San Francisco and a Bachelor of Arts in Eastern Studies and Psychology from Lone Mountain College in San Francisco.
DISCLAIMER: These statements have not been evaluated by the United States Food and Drug Administration. The U.S. federal government (including the FDA) maintains that cannabis is a Schedule 1 drug under the federal Controlled Substances Act, with no accepted medical use, despite the mounting evidence from the international medical community. As a result, our products cannot go through FDA testing that would enable us to make health claims, and we are required to state that Constance LifeSciences Corp. & Constance Pure Botanical Extracts products are not intended to diagnose, treat, cure, or prevent any disease, illness or medical condition. Constance LifeSciences Corp. & Constance Pure Botanical Extracts makes no healing, curative or medical claims or warranties regarding its products. If you have a medical condition or illness, please consult your physician.